The handbook of biological therapy : a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology /

Mostrar otras versiones (1)

Drugs produced by molecular biological techniques, called the 'biologics', differ from the usual chemical medications. Their optimum use, and the detection and managemenet of adverse events, pose a significant challenge to the clinician. Licences for new biologics continue to be granted fo...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Kirkham, Bruce
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Oxford : Oxford University Press, 2008.
Temas:
Biological products > Therapeutic use.
Tumor necrosis factor > Inhibitors.
Tumor Necrosis Factor-alpha > therapeutic use
Gastrointestinal Diseases > therapy
Rheumatic Diseases > therapy
Skin Diseases > therapy
Biological Therapy
Biothérapie.
Tractus gastro-intestinal > Maladies > Traitement.
MEDICAL > Pharmacology.
Biological products > Therapeutic use
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Preface; Foreword; Contents; TNF
  • tumour necrosis factor [alpha]; Mode of action of anti-TNF; TNF-blocking drugs in clinical use; TNF-blocking drugs not in clinical use; Section 1 TNF-blocker safety; Increased risk of infection; Tuberculosis; Opportunistic infections; Injection-site reactions; Allergic, hypersensitivity reactions, anaphylactic responses; Psoriasis; Infusion reactions (infliximab); Malignancy and lymphoproliferative conditions; Drug-induced lupus-like reactions; Anti-drug antibodies (immunogenicity); Congestive heart failure; Neurological; Hepatobiliary; Use in pregnancy; Lactation.
  • RespiratoryVaccinations; Use of TNF-blockers with other medications; Haematological; Postmarketing safety experience in Crohn's disease; Section 2 Rheumatology; Rheumatoid arthritis; Other rheumatological conditions; TNF-blocking therapy in ankylosing spondylitis and psoriatic arthritis; Ankylosing spondylitis; Psoriatic arthritis; Adalimumab (Humira); Etanercept (Enbrel); Infliximab (Remicade); Certolizumab pegol (Cimzia); Abatacept (Orencia); Anakinra (Kineret); B-cell depletion: Rituximab (Rituxan® [USA], MabThera® [Europe, Asia, South America]); Section 3 Dermatology; Psoriasis.
  • Approaches to managementAssessing disease severity; Important differences between psoriasis and rheumatoid arthritis; Biological therapy for psoriasis; Etanercept (Enbrel); Infliximab (Remicade); Adalimumab (Humira); Efalizumab (Raptiva); Alefacept (Amevive); Section 4 Gastroenterology; Biological therapy in inflammatory bowel disease and Crohn's disease; Adalimumab (Humira); Infliximab (Remicade); Natalizumab (Tysabri); Certolizumab pegol (Cimzia); Index; A; B; C; D; E; G; H; I; K; L; M; N; O; P; R; S; T; U; V.

Ejemplares similares